Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $56.71 Consensus Target Price from Brokerages

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $56.7143.

Several research analysts have commented on IMCR shares. Wall Street Zen raised shares of Immunocore from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Zacks Research raised shares of Immunocore from a “strong sell” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Jefferies Financial Group downgraded shares of Immunocore from a “buy” rating to a “hold” rating and decreased their price target for the stock from $48.00 to $33.00 in a research note on Monday, March 16th. Needham & Company LLC lifted their price target on shares of Immunocore from $71.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Immunocore in a research note on Monday, April 20th.

Immunocore Stock Performance

NASDAQ IMCR opened at $28.60 on Friday. The stock’s 50-day simple moving average is $29.32 and its two-hundred day simple moving average is $31.94. Immunocore has a twelve month low of $27.56 and a twelve month high of $40.71. The company has a quick ratio of 4.15, a current ratio of 4.18 and a debt-to-equity ratio of 1.00. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -52.00 and a beta of 0.74.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.51. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The business had revenue of $106.68 million for the quarter, compared to the consensus estimate of $145.20 million. During the same quarter last year, the business posted $0.10 earnings per share. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. Research analysts forecast that Immunocore will post 0.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in IMCR. Harbour Investments Inc. boosted its holdings in shares of Immunocore by 60.2% during the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after buying an additional 388 shares in the last quarter. DNB Asset Management AS boosted its stake in Immunocore by 6.4% in the 3rd quarter. DNB Asset Management AS now owns 8,116 shares of the company’s stock worth $295,000 after purchasing an additional 488 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Immunocore by 37.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock worth $74,000 after purchasing an additional 572 shares in the last quarter. R Squared Ltd boosted its stake in Immunocore by 7.4% in the 4th quarter. R Squared Ltd now owns 8,849 shares of the company’s stock worth $307,000 after purchasing an additional 606 shares in the last quarter. Finally, Leonteq Securities AG bought a new position in Immunocore in the 4th quarter worth about $30,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.